These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15743039)

  • 1. Effects of X-ray irradiation on the overexpression of HER-2/Erb-B2 on breast cancer cell lines.
    Juranić ZD; Borojević N; Jovanović D; Stanojević-Bakić N; Zizak Z; Nesković-Konstantinović Z; Sarić M; Stanojković T; Raonić T; Milosević D
    J Exp Clin Cancer Res; 2004 Dec; 23(4):675-80. PubMed ID: 15743039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
    Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
    Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
    Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
    Glazyrin A; Shen X; Blanc V; Eliason JF
    J Histochem Cytochem; 2007 Jan; 55(1):25-33. PubMed ID: 16957165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
    McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
    Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
    Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
    Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
    Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
    Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
    Cheyne RW; Trembleau L; McLaughlin A; Smith TA
    Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
    Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
    Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.